Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arcturus, Ultragenyx ally in rare disease pact worth up to $1.6bn

Executive Summary

RNA-focused start-up Arcturus Therapeutics Inc. (ATI) and fellow rare disease therapeutics developer Ultragenyx Pharmaceutical Inc. will collaborate on the discovery and development of messenger RNA (mRNA) therapeutics for up to ten select undisclosed rare disease targets, using Arcturus' UNA (Unlocked Nucleomonomer Agent) and LUNAR enabling technologies.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register